142
Participants
Start Date
June 30, 2011
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
DN24-02
DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
Standard of Care
Observation only until documentation of disease recurrence.
NYU Clinical Cancer Center, NYU Langone Medical Center, New York
Memorial Sloan Kettering, New York
Mount Sinai School of Medicine Department of Urology, New York
Mount Sinai School of Medicine, New York
Columbia University Medical Center, New York
Weill Cornell Medical College, New York
Associated Medical Professionals of New York, PLLC, Syracuse
Associated Medical Professionals of NY, PLLC, Oneida
Roswell Park Cancer Institute, Buffalo
University of Rochester Medical Center, Rochester
Urology Health Specialists, LLC, Bryn Mawr
Thomas Jefferson University, Philadelphia
Fox Chase Cancer Center, Philadelphia
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Johns Hopkins Hospital, Baltimore
Urology of Virginia, PLLC, Virginia Beach
Sentara Leigh Hospital, Norfolk
UNC Health Care, NC Cancer Hospital, Chapel Hill
Duke University, Durham
Medical University of South Carolina, Charleston
Emory Department of Urology, The Emory Clinic Inc, Emory University Hospital, Atlanta
American Red Cross, Atlanta
Urological Research Network, Hialeah
University of Miami Cancer Center, Miami
H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa
Urology Associates, P.C., Nashville
Vanderbilt University Medical Center, Nashville
TriState Urologic Services PSC, Inc. dba TUG Research, Cincinnati
Hoxworth Blood Center, Cincinnati
Jewish Hospital, Cincinnati
Indiana University, Indianapolis
Michigan Institute of Urology, Troy
University of Wisconsin Carbone Cancer Center, Madison
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
University of Chicago Medical Center, Chicago
University of Kansas Cancer Center, Westwood
Kansas City Urology Care, Overland Park
GU Research Center, LLC, Omaha
Urologic Specialists of Oklahoma, Tulsa
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado, Anschutz Cancer Pavilion, Aurora
The Urology Center of Colorado, Denver
Mayo Clinic Hospital, Phoenix
Mayo Clinic Arizona, Scottsdale
USC/Norris Comprehensive Cancer Center, Los Angeles
City of Hope Medical Center, Duarte
Genesis Research, San Diego
Stanford University Hospital, Stanford
OHSU Knight Cancer Institute Hematology Oncology, Beaverton
Providence Medical Center, Portland
Oregon Urology Institute, Springfield
Virginia Mason Medical Center, Seattle
UW Medical Center, Seattle
Neag Comprehensive Cancer Center/University of Connecticut Health Center, Farmington
Yale University School of Medicine, New Haven
Dana Farber Cancer Institute, Boston
Lahey Clinic, Burlington
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
The Ohio State University Wexner Medical Center, James Cancer Hospital, Martha Morehouse Medical Plaza, Ohio State University Dept of Urology, Columbus
Lead Sponsor
Dendreon
INDUSTRY